A Boston-based team published proof Thursday that one of the most alluring ideas in cancer care can work: Exceedingly rare tumor cells can be filtered from a patient’s blood sample and used to noninvasively monitor the evolution of cancer and identify the most promising treatments. Daniel Haber, the Kurt J. Isselbacher/Peter D. Schwartz Professor of Oncology at Massachusetts General Hospital, oversaw the study.
News & Research
